Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial
Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor-T cell (CAR-T) immunotherapy approved for patients (pts) with relapsed/refractory multiple myeloma (RRMM). In the phase 3 trial CARTITUDE-4 (NCT04181827), cilta-cel demonstrated improved efficacy vs standard of care (SOC; daratumumab plus pomalidomide and dexamethasone [DPd] or pomalidomide plus bortezomib and dexamethasone [PVd]) with an overall response rate (ORR) of 84.6% vs 67.3% and ≥complete response (CR) of 73.1% vs 21.8%. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Doris K Hansen, Xiaoxiao Lu, Omar Castaneda, Sonja Sorensen, Saad Z. Usmani, Eileen Zhang, Stephen Huo, Sundar Jagannath Tags: 519 Source Type: research
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1 –3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 Trial
CARTITUDE-4 (NCT04181827) is a phase 3 trial comparing ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen chimeric antigen receptor-T cell (CAR-T) therapy, with standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in patients (pts) with lenalidomide (len)-refractory multiple myeloma (MM). Pts in the cilta-cel arm had significantly improved progression-free survival (PFS), higher rates of ≥complete response (CR), and higher overall response rate (ORR) versus SOC in the intent-to-treat (ITT) set. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: M Hasib Sidiqi, Paolo Corradini, Duncan Purtill, Hermann Einsele, Binod Dhakal, Lionel Karlin, Salomon Manier, Shinsuke Iida, Sebastian Giebel, Simon J Harrison, Brea Lipe, Dr. Abdullah Mohammad Khan, Jordan M Schecter, Carolyn C Jackson, Tzu-min Yeh, Arn Tags: 514 Source Type: research
Predicting colorectal cancer prognosis based on long noncoding RNAs of disulfidptosis genes
CONCLUSION: Our findings emphasizes the role of disulfidptosis in regulating tumor development, therapeutic response, and patient survival in CRC patients. For the clinical treatment of CRC, these important LncRNAs could serve as viable therapeutic targets.PMID:38292658 | PMC:PMC10823938 | DOI:10.5306/wjco.v15.i1.89 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Kui-Ling Wang Kai-Di Chen Wen-Wen Tang Ze-Peng Chen Yu-Ji Wang Guo-Ping Shi Yu-Gen Chen Source Type: research
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT
Bone Marrow Transplantation, Published online: 31 January 2024; doi:10.1038/s41409-023-02160-8In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - January 31, 2024 Category: Hematology Authors: Meral Beksac Diderik-Jan Eikema Linda Koster Cyrille Hulin Xavier Poir é Rose-Marie Hamladji Tomasz Gromek Ali Bazarbachi Zubeyde Nur Ozkurt Thomas Pabst Tarek Ben Othman J ürgen Finke Olga Pirogova Depei Wu Amjad Hayat Inken Hilgendorf Eleni Tholouli L Source Type: research
Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
ConclusionThis meta-analysis suggests that daratumumab-containing immunotherapy is superior to RVD in the depth of treatment efficacy, progression-free survival, and lower treatment-related discontinuation rates. Limited by the lack of head-to-head clinical trials, this conclusion needs to be verified by concurrent cohort studies. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - January 25, 2024 Category: Cancer & Oncology Source Type: research
Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors
Int J Hematol. 2024 Jan 21. doi: 10.1007/s12185-023-03705-9. Online ahead of print.ABSTRACTResistance to proteasome inhibitors (PIs) has emerged as an important clinical issue. We investigated the mechanisms underlying multiple myeloma (MM) cell resistance to PIs. To mimic their pharmacokinetic/pharmacodynamic (PK/PD) profiles, MM cells were treated with bortezomib and carfilzomib for 1 h at concentrations up to 400 and 1,000 nM, respectively. Susceptibility to these PIs markedly varied among MM cell lines. Pulsatile treatments with PIs suppressed translation, as demonstrated by incorporation of puromycin at 24 h in PI-sus...
Source: International Journal of Hematology - January 21, 2024 Category: Hematology Authors: Kimiko Sogabe Shingen Nakamura Yoshiki Higa Hirokazu Miki Asuka Oda Tomoko Maruhashi Ryohei Sumitani Masahiro Oura Mamiko Takahashi Masafumi Nakamura Yusaku Maeda Tomoyo Hara Hiroki Yamagami Shiro Fujii Kumiko Kagawa Shuji Ozaki Kiyoe Kurahashi Itsuro End Source Type: research
An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
CONCLUSION: This is the first study to evaluate the safety and efficacy of this repurposed drug combination in this very difficult-to-treat population of relapsed and refractory MM. This was an overall negative study with no ORR observed. Fortunately, 1 patient experienced an SD response, allowing this combination to stabilize their disease until another novel therapy on a clinical trial was available.PMID:38220589 | DOI:10.1016/j.clml.2024.01.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 14, 2024 Category: Cancer & Oncology Authors: Ibrahim Alodhaibi Sikander Ailawadhi Gabriel P Burbano Patrick J O'Brien Francis K Buadi Suzanne Hayman Shaji K Kumar Wilson I Gonsalves Source Type: research
Comparison of long-term outcomes after first HLA-mismatched unrelated donor transplantation with single unrelated cord blood transplantation using reduced-intensity or reduced-toxicity conditioning
CONCLUSION: MMUD with better GVHD prophylaxis might be preferred over CB in patients with older age and comorbidities.PMID:38185390 | DOI:10.1016/j.trim.2024.101988 (Source: Transplant Immunology)
Source: Transplant Immunology - January 7, 2024 Category: Transplant Surgery Authors: Masatomo Kuno Hideo Koh Kentaro Ido Kazuki Sakatoku Yosuke Makuuchi Teruhito Takakuwa Asao Hirose Hiroshi Okamura Mitsutaka Nishimoto Yasuhiro Nakashima Mika Nakamae Masayuki Hino Hirohisa Nakamae Source Type: research
Comparison of long-term outcomes after first HLA-mismatched unrelated donor transplantation with single unrelated cord blood transplantation using reduced-intensity or reduced-toxicity conditioning
CONCLUSION: MMUD with better GVHD prophylaxis might be preferred over CB in patients with older age and comorbidities.PMID:38185390 | DOI:10.1016/j.trim.2024.101988 (Source: Transplant Immunology)
Source: Transplant Immunology - January 7, 2024 Category: Transplant Surgery Authors: Masatomo Kuno Hideo Koh Kentaro Ido Kazuki Sakatoku Yosuke Makuuchi Teruhito Takakuwa Asao Hirose Hiroshi Okamura Mitsutaka Nishimoto Yasuhiro Nakashima Mika Nakamae Masayuki Hino Hirohisa Nakamae Source Type: research
Comparison of long-term outcomes after first HLA-mismatched unrelated donor transplantation with single unrelated cord blood transplantation using reduced-intensity or reduced-toxicity conditioning
CONCLUSION: MMUD with better GVHD prophylaxis might be preferred over CB in patients with older age and comorbidities.PMID:38185390 | DOI:10.1016/j.trim.2024.101988 (Source: Transplant Immunology)
Source: Transplant Immunology - January 7, 2024 Category: Transplant Surgery Authors: Masatomo Kuno Hideo Koh Kentaro Ido Kazuki Sakatoku Yosuke Makuuchi Teruhito Takakuwa Asao Hirose Hiroshi Okamura Mitsutaka Nishimoto Yasuhiro Nakashima Mika Nakamae Masayuki Hino Hirohisa Nakamae Source Type: research
An Open-Label Phase 1 Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
In preclinical models, combining a GLUT4 inhibitor with an oxidative phosphorylation inhibitor shows synergistic therapeutic potential against multiple myeloma (MM). Thus, this study evaluated the safety and tolerability of repurposing metformin, a complex I inhibitor, and nelfinavir, a GLUT4 inhibitor, in combination with bortezomib for the treatment of relapsed/refractory MM that had progressed on all standard of care (SOC) therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 6, 2024 Category: Hematology Authors: Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel Perez Burbano, Patrick J. O'Brien, Francis K. Buadi, Suzanne Hayman, Shaji K. Kumar, Wilson I. Gonsalves Tags: Original Study Source Type: research
An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
A therapeutic combination of metformin, nelfinavir, and bortezomib is feasible for multiple myeloma patients with relapsed and/or refractory disease. While no dose-limiting toxicities were observed, no objective responses were observed either in the dose levels evaluated in this study. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 6, 2024 Category: Hematology Authors: Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel P. Burbano, Patrick J. O'Brien, Francis K. Buadi, Suzanne Hayman, Shaji K. Kumar, Wilson I. Gonsalves Tags: Original Study Source Type: research
Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials
This study investigated the association of PPI use with survival and adverse effects in MM patients across three randomized-control trials initiating daratumumab, lenalidomide, or bortezomib combination treatments. Cox proportional hazard analysis and logistic regression were employed to assess the associations with treatment outcomes, while adjusting for age, sex, weight, MM international staging system stage, ECOG-performance status, comorbidity count, and presence of gastrointestinal disorders. Pooled data involving 1804 patients revealed that 557 (32%) used PPIs at baseline. PPI use was independently associated with wo...
Source: Cancer Control - January 5, 2024 Category: Cancer & Oncology Authors: Sara A Almansour Mohammad A Y Alqudah Ziad Abuhelwa Humaid O Al-Shamsi Mohammad H Semreen Yasser Bustanji Nelson C Soare Ross A McKinnon Michael J Sorich Ashley M Hopkins Ahmad Y Abuhelwa Source Type: research
Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma
AbstractLeiomyosarcoma (LMS) is an aggressive mesenchymal malignancy, which originates from the smooth muscle cells or from the precursor mesenchymal stem cells that potentially differentiate into smooth muscle cells. LMS is one of the most common sarcomas. LMS has genomic instability, reflecting complex and unbalanced karyotypes, and the cytogenetic and molecular changes in LMS are not consistent. The standard treatment of the primary LMS is complete resection, and the metastasis is often observed even after curative surgery. Patient-derived cancer models are a key bioresource to develop a novel therapy, and we aimed to e...
Source: Human Cell - January 1, 2024 Category: Cytology Source Type: research
A Case Study Of The Kinetics Of Donor-derived Cell-free DNA Following Plasmapheresis And Bortezomib
We present a case of a 25-year old female who underwent OHT 18 years ago presenting with chest pain. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Christopher Aseervatham, Colton Smith, Pinak Joshi, Kenneth Dulnuan Tags: 178 Source Type: research
